Compositions and methods of treatment for lytic and lysogenic viruses
AssigneeExcision Biotherapeutics, Inc.
InventorThomas MALCOLM
Life of this patent
Estimating the term…
Loading patent…
AssigneeExcision Biotherapeutics, Inc.
InventorThomas MALCOLM
Estimating the term…
A composition for treating a lysogenic virus, including isolated nucleic acid encoding two or more gene editors chosen from gene editors that target viral DNA, gene editors that target viral RNA, and combinations thereof. A composition for treating a lytic virus, including isolated nucleic acid encoding at least one gene editor that targets viral DNA and a viral RNA targeting composition. A composition for treating both lysogenic and lytic viruses, including isolated nucleic acid encoding two or more gene editors that target viral RNA, chosen from CRISPR-associated nucleases, Argonaute endonuclease gDNAs, C2c2, RNase P RNA, and combinations thereof. A composition for treating lytic viruses, including isolated nucleic acid encoding two or more gene editors that target viral RNA and a viral RNA targeting composition. Methods of treating a lysogenic virus or a lytic virus, by administering the above compositions to an individual having a virus and inactivating the virus.
1-60. (canceled)
A composition for treating a human immunodeficiency virus (HIV) infection, comprising a nucleic acid encoding Cas9 or Cpf1 and a nucleic acid encoding one or more gene editors that target a viral RNA.
A method of treating a human immunodeficiency virus (HIV) infection, comprising administering a composition comprising a nucleic acid encoding Cas9 or Cpf1 and a nucleic acid encoding one or more gene editors that target viral RNA.
Dependencies are inferred from the claim text.